GV20 Therapeutics is the US branch of GV20 Oncotherapy. The company utilizes high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20's proprietary antibody drug discovery engine has helped establish a solid portfolio of immuno-oncology antibody drug candidates for cancer treatment.

Pharmaceutical

GV20 Therapeutics

Shirley Liu

Xihao Hu

Wei Yang

Huawei Qiu

Xingfeng Bao

Jie Chen

Karim Benhadji

Sherlock Hu

Ying Gong

Ted Xiao

The executive team at GV20 Therapeutics has a history of experience in target discovery, molecular biology, and medicine. They have also been visiting students at Tsinghua University and Cornell University. Their education histories include degrees in biochemistry, cell biology, computer science, and biomathematics, bioinformatics, and computational biology.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at GV20 Therapeutics

Leadership Team

Board of Directors